# A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

> **NCT07035353** · — · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 200 (estimated)

## Conditions studied

- HER2 Overexpression
- Advanced Stage Breast Cancer
- Low Expression of HER2

## Interventions

- **DRUG:** T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.

## Key facts

- **NCT ID:** NCT07035353
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-05-01
- **Final completion:** 2035-05-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07035353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07035353, "A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07035353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*